Author: Gan & Lee Pharmaceuticals

A New Paradigm for Long-Term Weight Management: Once-Monthly Bofanglutide Maintenance Therapy Delivers Positive Results in Weight Control and Maintenance Over 24 Weeks — Gan & Lee Pharmaceuticals’ GRADUAL-3 Study Meets Its Primary Endpoint

November 4, 2026
First Participant Dosed in First-in-Human Phase 1 Study of GZC8072, a Novel Ultra-Long-Acting Once-Weekly Oral Peptide GLP-1 RA

September 9, 2026

A New Paradigm for Long-Term Weight Management: Once-Monthly Bofanglutide Maintenance Therapy Delivers Positive Results in Weight Control and Maintenance Over 24 Weeks — Gan & Lee Pharmaceuticals’ GRADUAL-3 Study Meets Its Primary Endpoint